Risk Management



Removal of abnormal cells from eye surface

Removal of abnormal cells from surface of eye consent form can be used when treating OSSN (ocular surface squamous neoplasia) and CIN (conjunctival intraepithelial neoplasia). It is written in plain language to make it easier for patients to understand.

We thank OMIC Director Steven I. Rosenfeld, MD, for his assistance in developing this form.

 

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

#1. Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $20 Million to our members through dividends.

61864684